Corcept Therapeutics Announces First Patient Dosed in Phase 3 Trial of Relacorilant

Corcept Therapeutics (NASDAQ:CORT), a company engaged in the discovery, development and commercialization of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the stress hormone cortisol, today announced that it dosed the first patient in the Phase 3 trial of relacorilant to treat patients with Cushing’s syndrome.

As quoted in the press release:

“We are excited to enroll the first patient in relacorilant’s Phase 3 trial,” said Joseph K. Belanoff, MD, Corcept’s Chief Executive Officer.  “Patients in Phase 2 experienced significant clinical benefit without Korlym’s serious off-target effects – endometrial thickening, vaginal bleeding and hypokalemia.  Confirming these results in Phase 3 would constitute a major medical advance.”

“I also want to thank our development team, and especially our Chief Medical Officer, Dr. Robert S. Fishman, for their tireless efforts in advancing relacorilant and our other product candidates,” said Dr. Belanoff.  “Our clinical programs are poised to make significant progress in a wide variety of serious disorders – Cushing’s syndrome, pancreatic, ovarian and prostate cancer, non-alcoholic steato-hepatitis (NASH) and antipsychotic-induced weight gain.  Patients with these serious disorders have few good options.  If we are successful in developing treatments for them, it will be in no small part because of Bob’s insight, and hard work.”  As announced earlier today, Dr. Fishman, will be stepping down from his position as Corcept’s Chief Medical Officer, effective January 31st, 2019.

Click here to read the full press release.